

Hand Delivery June 5, 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Yu et al.

Application No.: 09/507,968

Filed: February 22, 2000

For:

Neutrokine-alpha and

Neutrokine-alpha Splice Variants

Croup Art Unit: Not assigned

Examiner: Not assigned

Itny Docket No.: PF343P3

RESPONSE TO NOTICE TO FILE MISSING PARTS

Assistant Commissioner for Patents **BOX MISSING PARTS** Washington, D.C. 20231

Sir:

In response to the Notice to File Missing Parts mailed 4 April 2000, submitted herewith is an executed Declaration and Power of Attorney for entry into the abovereferenced application.

In addition, the Commissioner is hereby authorized to charge the late filing fee surcharge of \$130.00, as set forth in 37 C.F.R. § 1.16(e), and any other fee deemed necessary. to Deposit Account No. 08-3425. A duplicate of this sheet is enclosed.

Lastly, enclosed are 25 pages of sequence listing, and a computer-readable diskette containing same, to comply with the requirements for nucleotide and/or amino acid disclosure as set forth in 37 C.F.R. 1.821-1.825. Applicants hereby state under 37 C.F.R. §§1.821(f) and 1.825(b) that the hard copy of the sequence listing filed with the subject application on February 22, 2000, and the copy of the sequence listing and diskette submitted herewith, are identical. Moreover, applicants hereby certify under 37 C.F.R. §§1.821(g) and 1.825(a) that the enclosed sequence listing contains no new matter.

Respectfully submitted,

Hoover

(Reg. No. 40,302)

Attorney for Applicants


Human Genome Sciences, Inc. 9410 Key West Avenue

Rockville, Maryland 20850 301-309-8504 (telephone)



FORMALITIES LETTER







UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENT AND TRADEMARKS Washington, D.C. 20231

FIRST NAMED APPLICANT ATTORNEY DOCKET NUMBER FILING/RECEIPT DATE APPLICATION NUMBER

09/507,968

02/22/2000

Guo-Liang Yu

PF343P3

Kenley K. Hoover, Esq. Human Genome Sciences, Inc. 9410 Key West Avenue Rockville, MD 20850



Date Mailed: 04/04/2000

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- · The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-1123
- For CRF Submission Help, call (703) 308-4212
- Patentin Software Program Support
- - For Technical Assistance, call (703) 287-0200
- - To Purchase Patentin Software, call (703) 306-2600

The balance due by applicant is \$ 130.

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

36/06/2000 YPOLITE1 00000012 130°00 CH

083425



PART 2 - COPY TO BE RETURNED WITH RESPONSE





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Yu et al.

Application No.: 09/507,968

Group Art Unit:

Filed: February 22, 2000

Examiner: Not assigned

For:

Neutrokine-alpha and

Neutrokine-alpha Splice Variants

Attny Docket No.: FF343P3

REQUEST FOR CORRECTION OF FILING RECEIPT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Applicants respectfully request that the enclosed mig receipt be corrected. Specifically, after "Continuing Data as Claimed by Applicant," please correct "THIS APPLICATION IS A CIP OF 09/225,794 01/05/1999" to read -- THIS APPLICATION IS A CIP OF 09/255,794 02/23/99--.

The requested correction is indicated in red ink on the enclosed duplicate of the filing receipt.

No fee is believed due in connection with this request. However, if a fee is deemed necessary, please charge such fee to Deposit Account No. 08-3425. A duplicate of this sheet is enclosed.

Respectfully submitted,

Kenley K Hoover Attorney for Applicants (Reg. No. 40,302)

Human Genome Sciences, Inc.

9410 Key West Avenue Rockville, Maryland 20850 301-309-8504 (telephone)



FILING RECEIPT

OC000000005027834



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: ASSISTANT SECRETARY AND

COMMISSIONER OF PATENT AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/507,968	02/22/2000	1643	1014	PE343D3	16	25	6

EULIVEL

Kenley K. Hoover, Esa. Human Genome Sciences, Inc. 9410 Kev West Avenue Rockville, MD 20850

HGS PATENT DEPT

Date Mailed: 04/04/2000

Receipt is acknowledged of this nonprovisarial Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "N tice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate an ther Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Guo-Liang Yu, Berkeley, CA; Reinhard Ebner, Gaithersburg, MD; Jian Ni, Rockville, MD; Craig A. Rosen, Laytonsville, MD;

09/255,794 02/23/99 **Continuing Data as Claimed by Applicant**

THIS APPLICATION IS A CIP OF 09/225,794 04/05/1999 WHICH CLAIMS BENEFIT OF 60/122,388 03/02/1999 WHICH CLAIMS BENEFIT OF 60/124,097 03/12/1999 WHICH CLAIMS BENEFIT OF 60/126,599 03/26/1999 WHICH CLAIMS BENEFIT OF 60/127,598 04/02/1999 WHICH CLAIMS BENEFIT OF 60/130,412 04/16/1999 WHICH CLAIMS BENEFIT OF 60/130,696 04/23/1999 WHICH CLAIMS BENEFIT OF 60/131,278.04/27/1999 WHICH CLAIMS BENEFIT OF 60/131,673 04/29/1999 WHICH CLAIMS BENEFIT OF 60/136,784 05/28/1999 WHICH CLAIMS BENEFIT OF 60/142,659 07/06/1999 WHICH CLAIMS BENEFIT OF 60/145,824 07/27/1999 WHICH CLAIMS BENEFIT OF 60/167,239 11/24/1999 WHICH CLAIMS BENEFIT OF 60/168,624 12/03/1999 WHICH CLAIMS BENEFIT OF 60/171,108 12/16/1999 WHICH CLAIMS BENEFIT OF 60/171,626 12/23/1999 WHICH CLAIMS BENEFIT OF 60/176,015 01/14/2000

F reign Applicati ns

If Required, Foreign Filing Lic nse Granted 04/04/2000

Title

Neutrokine-alpha and neutrokine-alpha splice variant

Pr liminary Class

439

Data entry by : DAY, MARIAN

Team: OIPE

JUN 0 5 2000 E

Date: 04/04/2000

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37 Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "impr vements in" or "relating t" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).

- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231